ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Rochester, MN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Rochester, MN, USA:

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Lenalidomide

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Rochester, Minnesota, United States and 145 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Active, not recruiting
Multiple Myeloma
Drug: Isatuximab
Drug: CC-92480

Phase 1, Phase 2

Celgene
Celgene

Rochester, Minnesota, United States and 48 other locations

trial is a phase 1b/2, open-label, multicenter study of GC012F, a CD19/BCMA dual CART-cell therapy, in adult subjects with relapsed/refractory Multiple...

Enrolling
Relapsed/ Refractory Multiple Myeloma
Biological: GC012F

Phase 1, Phase 2

Gracell Biotechnologies

Rochester, Minnesota, United States and 7 other locations

The purpose of this research study is to evaluate a treatment regimen called IRD which will be given to participants after their stem cell transplant...

Active, not recruiting
Multiple Myeloma
Biological: Ixazomib
Drug: Dexamethasone

Phase 2

The Washington University
The Washington University

Rochester, Minnesota, United States and 9 other locations

versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...

Active, not recruiting
Multiple Myeloma
Biological: bb2121
Drug: Dexamethasone

Phase 3

Celgene
Celgene

Rochester, Minnesota, United States and 59 other locations

1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple...

Active, not recruiting
Multiple Myeloma
Biological: zevor-cel

Phase 1, Phase 2

CARsgen Therapeutics

Rochester, Minnesota, United States and 12 other locations

This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-383B, a BCMA x CD3 T-cell engaging bisp...

Active, not recruiting
Multiple Myeloma
Drug: TNB-383B

Phase 1, Phase 2

TeneoOne

Rochester, Minnesota, United States and 13 other locations

progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab SC
Drug: Daratumumab IV

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Rochester, Minnesota, United States and 211 other locations

versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...

Enrolling
Multiple Myeloma
Drug: Fludarabine
Drug: Daratumumab

Phase 3

Stichting European Myeloma Network

Rochester, Minnesota, United States and 126 other locations

Locations recently updated

Multiple Myeloma (MM) is a cancer of the blood's plasma cells ( blood cell). The cancer is typically found in the bones and bone ma...

Enrolling
Multiple Myeloma
Drug: ABBV-383

Phase 1

TeneoOne

Rochester, Minnesota, United States and 28 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems